Biotechnology

Silexion Therapeutics

Silexion Therapeutics released FY2025 Q4 earnings on March 17 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.4022 (forecast USD -1.12)

Silexion Therapeutics released FY2025 annual earnings on March 17 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -8.9596 (forecast USD -6.035)

Maxim Group Analyst Reiterates Buy Rating on Silexion Therapeutics

Silexion Therapeutics released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.8799 (forecast USD -3.4)

Analyst Rahman Covers Healthcare Industry and Focuses on Specific Stocks

Silexion Therapeutics Announces 99.7% Inhibition Rate of SIL204 in Multiple KRAS Mutant Cancer Cells

Silexion and Wainwright Sign Market Issuance Agreement, Plans to Sell up to $13.17 Million in Common Stock

Silexion Announces Positive Preclinical Data for KRAS-Driven Cancers

Silexion Therapeutics completes preclinical study of SIL204

Silexion studies RNA interference treatment for other KRAS-driven tumors

Silexion advances in RNA interference therapy candidate research

Silexion Announces Research on RNA Interference Therapeutic Candidate

Silexion Therapeutics released FY2025 Q1 earnings on May 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.8389 (forecast USD -3.3)

Silexion Therapeutics Corp. Reports Strong Q1 Earnings and SIL204 Progress

Silexion Strengthens RNAi Cancer Treatment Collaboration

Silexion Advances RNAi Cancer Therapy Towards Clinical Trials

Silexion Advances SIL204 Clinical Trial Plan, Expected to Start Human Testing in the First Half of 2026

Silexion Announces Expanded Dual-Route Strategy, Plans to Start Human Trials in First Half of 2026

Silexion Announces Enhanced Dual-Pathway Strategy to Address Tumors, Human Trials Expected to Start in First Half of 2026

Paranovus ENT Tech

Fundrise Innovation Fund LLC

Robin Energy - WI

AleAnna

ENvue Medical

Sol-Gel Tech

Yimutian

Quantum Biopharma

CVD Equipment

T-REX 2X Inverse CRCL Daily Target ETF

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Silexion Therapeutics(SLXN.US)

Silexion Therapeutics Stock Performance Chart